| Nome |
# |
|
Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics)., file e2188be6-015d-4564-e053-6605fe0a49d6
|
683
|
|
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis, file e2188be5-f9d2-4564-e053-6605fe0a49d6
|
558
|
|
Interventional treatment of venous thromboembolism: a review., file e2188be6-0158-4564-e053-6605fe0a49d6
|
472
|
|
Retrievable vena cava filters: a clinical review., file e2188be6-0159-4564-e053-6605fe0a49d6
|
264
|
|
Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients., file e2188be6-015c-4564-e053-6605fe0a49d6
|
259
|
|
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines., file e2188be6-015a-4564-e053-6605fe0a49d6
|
192
|
|
Statins, fibrates, and venous thromboembolism: a meta-analysis., file e2188be5-fef4-4564-e053-6605fe0a49d6
|
190
|
|
Should the commonly accepted definition of "unprovoked venous thrombembolism" be revisited?, file e2188be6-015b-4564-e053-6605fe0a49d6
|
187
|
|
Folic acid supplementation and cardiovascular diseases, file e2188be6-a367-4564-e053-6605fe0a49d6
|
179
|
|
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry., file e2188be6-6206-4564-e053-6605fe0a49d6
|
137
|
|
The metabolic syndrome and the risk of thrombosis, file e2188be6-6204-4564-e053-6605fe0a49d6
|
129
|
|
Incidental Diagnosis of Deep Vein Thrombosis in Consecutive Patients Undergoing a CT Scan of the Abdomen: a Retrospective Cohort Study., file e2188be5-ffb4-4564-e053-6605fe0a49d6
|
127
|
|
Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study, file e2188be6-650e-4564-e053-6605fe0a49d6
|
119
|
|
Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry., file e2188be6-9502-4564-e053-6605fe0a49d6
|
116
|
|
Fluctuations in warfarin dose response after heart valve surgery: implications for cardiac rehabilitation., file e2188be6-6281-4564-e053-6605fe0a49d6
|
113
|
|
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty, file e2188be7-12d4-4564-e053-6605fe0a49d6
|
83
|
|
Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD, file e2188be5-fd08-4564-e053-6605fe0a49d6
|
82
|
|
Cardiovascular risk factors and venous thromboembolism: a meta-analysis., file e2188be5-f958-4564-e053-6605fe0a49d6
|
32
|
|
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial., file e2188be5-f959-4564-e053-6605fe0a49d6
|
28
|
|
Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET), file e2188be8-2775-4564-e053-6605fe0a49d6
|
27
|
|
Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease, file be4fdd12-3e7a-4722-8bcc-d8c805fbd618
|
20
|
|
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial., file e2188be5-fd39-4564-e053-6605fe0a49d6
|
18
|
|
Milvexian and other drugs targeting Factor XI: a new era of anticoagulation?, file effd442e-8aed-4136-9e0e-b2c27684b104
|
15
|
|
High-Sensitivity Cardiac Troponin T and the Diagnosis of Cardiovascular Disease in the Emergency Room: The Importance of Combining Cardiovascular Biomarkers with Clinical Data, file 04a7ca07-bee8-4324-9001-aa0e6ca35d6c
|
14
|
|
null, file e2188be8-1d16-4564-e053-6605fe0a49d6
|
13
|
|
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry, file 04440b81-851e-40ac-bdfa-d8534bd53bb3
|
10
|
|
Immune-mediated mechanisms in patients tested positive for SARS-CoV-2: Protocol for a multianalysis study, file 098b9e8a-3b39-4d02-9cc2-34fec85ff7dd
|
10
|
|
Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study., file 3ec6b835-c726-4bee-8a90-a81bb951878c
|
10
|
|
Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette-based survey, file 3ceefa7b-6d23-4ca9-8334-df57b5da909d
|
9
|
|
Timing of anticoagulation for portal vein thrombosis in liver cirrhosis: An Italian internist's perspective, file f93981d5-8be5-464d-9c46-4363a66e405b
|
8
|
|
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study, file 25b9550a-249d-4524-aacf-5882118ed94d
|
7
|
|
Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry, file 945e513e-65ac-499d-aa84-d1c47fafa114
|
7
|
|
Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial, file ca98622f-a4bf-4874-8522-46a5cea55f2c
|
7
|
|
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts, file e2188be7-95b8-4564-e053-6605fe0a49d6
|
7
|
|
Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: Rationale and design of the PLATO-VTE study, file fa696af9-fcf6-40b4-9260-5a9464ea4eed
|
7
|
|
Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register, file 94d3b794-13bc-4e48-b777-01ffb2fc72e8
|
6
|
|
COVID-19 pandemic affects the ability of negative D-dimer to identify venous thromboembolism patients at low risk of recurrence: insights from the Apidulcis study, file 374e06cf-a498-40a6-bd15-da3c0a037d36
|
5
|
|
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment, file e2188be6-9aa5-4564-e053-6605fe0a49d6
|
5
|
|
In vitro effects of Apixaban on 5 different cancer cell lines, file e2188be6-d9f9-4564-e053-6605fe0a49d6
|
4
|
|
Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy, file e2188be7-cd8d-4564-e053-6605fe0a49d6
|
4
|
|
null, file e2188be7-d24d-4564-e053-6605fe0a49d6
|
4
|
|
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study, file 8820fe89-ab82-4497-8d60-ef0702e2f390
|
3
|
|
SARS-CoV-2 B.1.1.7 reinfection after previous COVID-19 in two immunocompetent Italian patients, file e2188be7-cd88-4564-e053-6605fe0a49d6
|
3
|
|
RAPID SALIVARY TEST SUITABLE FOR A MASS SCREENING PROGRAM TO DETECT SARS-COV-2: A DIAGNOSTIC ACCURACY STUDY, file e2188be7-d4b5-4564-e053-6605fe0a49d6
|
3
|
|
Safety and effectiveness of biosimilar enoxaparin (Inhixa) for the prevention of thromboembolism in medical and surgical inpatients, file 000db8f5-9a55-41fa-85c5-996d7bbe4ad1
|
2
|
|
Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism, file aafae7a7-9229-4c6e-95f2-9895639a8388
|
2
|
|
Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study, file e2188be6-3a4b-4564-e053-6605fe0a49d6
|
2
|
|
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial, file e2188be6-9b5a-4564-e053-6605fe0a49d6
|
2
|
|
The association between neonatal ABO blood group and intraventricular hemorrhage in extremely low birth weight infants: A reply to a comment, file 1d788e75-89d8-4a51-bead-61c58c76b17e
|
1
|
|
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: Results of the prospective collaborative EPICA study: Reply, file 2159eef3-dd8e-4b67-83ff-04be7458aa31
|
1
|
|
DOACs use in extreme body-weighted patients: results from the prospective START-register, file 23f2d599-9882-485d-862f-1e7107eefe6e
|
1
|
|
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19, file 3f0fa67c-8a71-4ca8-b946-48d9620fa55a
|
1
|
|
Use of artificial intelligence and radiomics for risk stratification in patients with pulmonary embolism: New tools for an old problem, file a54d55c8-86b0-46ba-951c-1a805501e96b
|
1
|
|
Geographical and ethnoracial differences in venous thromboembolism and anticoagulation: An expanding horizon, file ba0051f4-54ed-492d-9a0a-f1f74e6552c6
|
1
|
|
Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon?, file d96ea985-d38d-4b50-81f0-978bf99bfd82
|
1
|
|
Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation, file e2188be7-fb27-4564-e053-6605fe0a49d6
|
1
|
|
Rates of venous thromboembolism and use of thromboprophylaxis after major orthopedic surgery in patients with congenital hemophilia A or B: a systematic review, file ea7af0c2-3762-47fa-9906-c26497d97293
|
1
|
| Totale |
4.193 |